J Gynecol Oncol.
2013 Jul;24(3):209-211. 10.3802/jgo.2013.24.3.209.
Bevacizumab and oral metronomic cyclophosphamide in platinum-resistant ovarian cancer
- Affiliations
-
- 1Unite Cancer de la Femme et Recherche Clinique, Hopitaux Universitaires Paris Centre, site Hotel-Dieu, Universite Paris Descartes, Paris, France. epujade@arcagy.org
- KMID: 2288525
- DOI: http://doi.org/10.3802/jgo.2013.24.3.209
Abstract
- No abstract available.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- The combination of intravenous bevacizumab and metronomic oral cyclophosphamide is an effective regimen for platinum-resistant recurrent ovarian cancer
- Improving Conventional or Low Dose Metronomic Chemotherapy with Targeted Antiangiogenic Drugs
- Early experiences with PD-1 inhibitor treatment of platinum resistant epithelial ovarian cancer
- A single-arm phase II study of olaparib maintenance with pembrolizumab and bevacizumab in BRCA non-mutated patients with platinum-sensitive recurrent ovarian cancer (OPEB-01)
- Response to Corcept’s retraction request on manuscript of “Relacorilant plus nab-paclitaxel for recurrent, platinum-resistant ovarian cancer: a cost-effectiveness study”
